Diarrhea in Oncology

Marion Debus

Last update: 12.06.2019

Diarrhea is a very common and often difficult to treat problem in the context of oncology. It is typically associated with a weakened life organization in the intestinal tract, expressed in regeneration disorders of the intestinal mucosa due to chemotherapy, radiation therapy or after bone marrow transplantation (GvHD). Diarrhea also occurs with infections which are more common in the context of a weakened immune system.

Among the chemotherapies that most frequently cause diarrhea are irinotecan and 5-fluorouracil. The causes of diarrhea after chemotherapy are manifold: motility, secretion and resorption disorders may all play a role. Diarrhea is also very common with the tyrosine kinase inhibitors commonly used today, such as imatinib. 

(Other causes, such as short bowel syndrome or pancreatic insufficiency, which also occur frequently in oncological patients, will not be considered here.)

A special form is diarrhea after rectal resection, which is difficult to influence and which develops due to the lack of reservoir function, something that often restricts the patient’s social activities in the long term. High doses of loperamide are often required, in many cases also Tinctura opii.

An increasingly diminished intervention of the soul body is expressed in accelerated intestinal passage and hypersecretion, which are often also accompanied by painful tenesmus in cases of physical damage (e.g., mucositis). The soul body no longer has a proper formative effect in the area of the weakened life organization and subsequently does not reach the physical level adequately either. There is a disturbance in the breathing equilibrium between the upbuilding resorption processes and the degenerative processes of secretion and movement.

The therapeutic approach

The therapeutic aim is to support upbuilding life processes and strengthen the structuring forces of the soul body in the area of the intestinal mucosa. The ‘I’-organization should be called upon to integrate and harmonize the exaggerated activity of the soul body. 

 

Research news

Phase IV trial: Kalium phosphoricum comp. versus placebo in irritability and nervousness 
In a new clinical study, Kalium phosphoricum comp. (KPC) versus placebo was tested in 77 patients per group. In a post-hoc analysis of intra-individual differences after 6 weeks treatment, a significant advantage of KPC vs. placebo was shown for characteristic symptoms of nervous exhaustion and nervousness (p = 0.020, p = 0.045 respectively). In both groups six adverse events (AE) were assessed as causally related to treatment (severity mild or moderate). No AE resulted in discontinuation in treatment. KPC could therefore be a beneficial treatment option for symptomatic relief of neurasthenia. The study has been published open access in Current Medical Research and Opinion
https://doi.org/10.1080/03007995.2023.2291169.


Further information on Anthroposophic Medicine